ES2164914T3 - Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar. - Google Patents
Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.Info
- Publication number
- ES2164914T3 ES2164914T3 ES96929318T ES96929318T ES2164914T3 ES 2164914 T3 ES2164914 T3 ES 2164914T3 ES 96929318 T ES96929318 T ES 96929318T ES 96929318 T ES96929318 T ES 96929318T ES 2164914 T3 ES2164914 T3 ES 2164914T3
- Authority
- ES
- Spain
- Prior art keywords
- patient
- immunotherapy
- treat
- containing antibodies
- specifically detect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
SE DESCRIBEN MEDICAMENTOS QUE CONTIENEN ANTICUERPOS CON AL MENOS UNA ESPECIFICIDAD Y QUE RECONOCEN EL ANTIGENO MHCII DE UN PACIENTE A TRATAR. ADEMAS, SE DESCRIBEN ANTICUERPOS CON DOS O MAS ESPECIFICIDADES, QUE RECONOCEN EL ANTIGENO MHCII DE UN PACIENTE, ASI COMO LAS COMPOSICIONES DIAGNOSTICAS QUE CONTIENEN ESTOS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19531346A DE19531346A1 (de) | 1995-08-25 | 1995-08-25 | Arzneimittel zur Immuntherapie, enthaltend Antikörper, die spezifisch das MHCII-Antigen eines zu behandelnden Patienten erkennen |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2164914T3 true ES2164914T3 (es) | 2002-03-01 |
Family
ID=7770409
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES96929318T Expired - Lifetime ES2164914T3 (es) | 1995-08-25 | 1996-08-23 | Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar. |
Country Status (8)
Country | Link |
---|---|
US (1) | US6294167B1 (es) |
EP (1) | EP0845998B1 (es) |
AT (1) | ATE208630T1 (es) |
DE (2) | DE19531346A1 (es) |
DK (1) | DK0845998T3 (es) |
ES (1) | ES2164914T3 (es) |
PT (1) | PT845998E (es) |
WO (1) | WO1997007819A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999002567A2 (en) * | 1997-07-08 | 1999-01-21 | Board Of Regents, The University Of Texas System | Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells |
DE19937264A1 (de) * | 1999-08-06 | 2001-02-15 | Deutsches Krebsforsch | F¶v¶-Antikörper-Konstrukte |
JP2003515323A (ja) * | 1999-11-18 | 2003-05-07 | オックスフォード バイオメディカ(ユーケイ)リミテッド | 抗 体 |
US20030086929A1 (en) * | 2001-10-11 | 2003-05-08 | Tso J. Yun | Treatment of prostate cancer by inhibitors of ATP synthase |
DE10261223A1 (de) * | 2002-12-20 | 2004-07-08 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen |
ES2417065T3 (es) | 2005-04-26 | 2013-08-05 | Trion Pharma Gmbh | Combinación de anticuerpos con glucocorticoides para el tratamiento del cáncer |
GB0509318D0 (en) * | 2005-05-06 | 2005-06-15 | Chiron Srl | TCR-independent activation of T cells |
GB0512225D0 (en) * | 2005-06-16 | 2005-07-27 | Univ Sheffield | Immunoglobulin molecules |
EP1820513A1 (en) | 2006-02-15 | 2007-08-22 | Trion Pharma Gmbh | Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies |
US7862813B2 (en) | 2006-07-29 | 2011-01-04 | Bjork Jr Robert Lamar | Bi-specific monoclonal antibody (specific for both CD3 and CD11b) therapeutic drug |
GB0803076D0 (en) * | 2008-02-20 | 2008-03-26 | Univ Ghent | Mucosal Membrane Receptor and uses thereof |
EP2241576A1 (en) | 2009-04-17 | 2010-10-20 | Trion Pharma Gmbh | Use of trifunctional bispecific antibodies for the treatment of tumors associated with CD133+/EpCAM+ cancer stem cells |
EP3915999A1 (en) * | 2014-03-13 | 2021-12-01 | Universität Basel | Carbohydrate ligands that bind to igm antibodies against myelin-associated glycoprotein |
BR112019010878A2 (pt) | 2016-11-29 | 2019-10-01 | Lindhofer Horst | combinação de anticorpos multifuncionais de redirecionamento de células t com moduladores de ponto de verificação imunológico e usos dos mesmos |
CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
CA3054079A1 (en) | 2017-02-20 | 2018-08-23 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
PE20220278A1 (es) | 2018-02-08 | 2022-02-25 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpos que se dirigen al receptor nkg2d |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0068790B1 (en) | 1981-06-25 | 1986-02-26 | The Board Of Trustees Of The Leland Stanford Junior University | Allele specific immunotherapeutic method and dosage form |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
-
1995
- 1995-08-25 DE DE19531346A patent/DE19531346A1/de not_active Ceased
-
1996
- 1996-08-23 PT PT96929318T patent/PT845998E/pt unknown
- 1996-08-23 EP EP96929318A patent/EP0845998B1/de not_active Expired - Lifetime
- 1996-08-23 DK DK96929318T patent/DK0845998T3/da active
- 1996-08-23 ES ES96929318T patent/ES2164914T3/es not_active Expired - Lifetime
- 1996-08-23 US US09/029,369 patent/US6294167B1/en not_active Expired - Lifetime
- 1996-08-23 AT AT96929318T patent/ATE208630T1/de active
- 1996-08-23 DE DE59608213T patent/DE59608213D1/de not_active Expired - Lifetime
- 1996-08-23 WO PCT/EP1996/003733 patent/WO1997007819A1/de active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
DE19531346A1 (de) | 1997-02-27 |
DK0845998T3 (da) | 2002-02-11 |
PT845998E (pt) | 2002-04-29 |
EP0845998A1 (de) | 1998-06-10 |
US6294167B1 (en) | 2001-09-25 |
ATE208630T1 (de) | 2001-11-15 |
WO1997007819A1 (de) | 1997-03-06 |
DE59608213D1 (de) | 2001-12-20 |
EP0845998B1 (de) | 2001-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2164914T3 (es) | Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar. | |
HUP9802212A2 (hu) | Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok | |
GB2301366B (en) | Antibodies against E-selectin | |
IL189629A0 (en) | Compositions containing human ctla-4 antibodies | |
NO982062L (no) | Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav | |
EP0671920A4 (en) | AN ANTI-IDIOTYPICAL ANTIBODY AND ITS USE IN THE DIAGNOSIS AND THERAPY OF HIV-RELATED DISEASES. | |
DK65293D0 (da) | Fremgangsmaade til administrering af taxol | |
CY1111193T1 (el) | Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους | |
FI964681A (fi) | Ihmisperäiset Lactobacillus-kannat, niitä sisältävät valmisteet ja niiden käytöt | |
IL138424A (en) | Covalently reactive antigen analogs and pharmaceutical compositions containing the same | |
GR3026219T3 (en) | Mouse monoclonal antibodies | |
ES2119185T3 (es) | Tratamiento de enfermedades micobacterianas por administracion de productos de la proteina bactericida/que aumenta la permeabilidad. | |
DE69426767D1 (de) | Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen. | |
DE69812100T2 (de) | Adenosin enthaltendes arzneimittel | |
AR004360A1 (es) | Composiciones farmaceuticas para la terapia de carcinomas del epitelio plano y un agente para ser empleado en estas composicines farmaceuticas. | |
BR0111024A (pt) | Composições e métodos para a terapia e diagnóstico de câncer de mama | |
EP1028754A4 (en) | PREVENTION OF IMMUNE REACTIVITY DUE TO DEPTH OR INHIBITION OF ANTIGENT PRESENTING CELLS | |
EP0955366A4 (en) | ANTIGENIC PROTEIN FROM MALASSEZIA | |
ES2013321A6 (es) | Un metodo de produccion de anticuerpos monoclonales | |
ATE344664T1 (de) | Verbesserte methode zur eradikation von helicobacter pylori | |
FR2646607B1 (fr) | Anticorps monoclonaux anti-b2 microglobuline | |
ES2173334T3 (es) | Composiciones que contienen bismuto, para la prevencion y tratamiento de trastornos gastrointestinales. | |
TR199901998T2 (xx) | 9,10-sekokolesta-5,7,10(19)-triyen-1,3-diyol veya alfakasidol�n kullan�m�. | |
DK0500921T3 (da) | Na-K-ATPase-inhiberende natriuretiske substanser | |
UA40213A (uk) | Спосіб індивідуальної оцінки ефективності сорбенту |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 845998 Country of ref document: ES |